Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Operating Income (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Operating Income for 12 consecutive years, with -$164.7 million as the latest value for Q4 2025.

  • Quarterly Operating Income fell 256.28% to -$164.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$393.3 million through Dec 2025, down 160.63% year-over-year, with the annual reading at -$393.3 million for FY2025, 160.63% down from the prior year.
  • Operating Income hit -$164.7 million in Q4 2025 for Viking Therapeutics, down from -$98.6 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$12.5 million in Q4 2021 to a low of -$164.7 million in Q4 2025.
  • Historically, Operating Income has averaged -$38.6 million across 5 years, with a median of -$25.5 million in 2023.
  • Biggest five-year swings in Operating Income: decreased 11.04% in 2021 and later plummeted 256.28% in 2025.
  • Year by year, Operating Income stood at -$12.5 million in 2021, then tumbled by 62.13% to -$20.3 million in 2022, then plummeted by 44.38% to -$29.3 million in 2023, then tumbled by 57.89% to -$46.2 million in 2024, then tumbled by 256.28% to -$164.7 million in 2025.
  • Business Quant data shows Operating Income for VKTX at -$164.7 million in Q4 2025, -$98.6 million in Q3 2025, and -$74.6 million in Q2 2025.